Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Also known as Nutropin AQ [somatropin (DNA origin) injection]
Nutropin AQ · 1 trial · 1 indication
| Name | Type | Description |
|---|---|---|
| Nutropin AQ [somatropin (DNA origin) injection] | DRUG | - |
Inclusion Criteria: * Ability of parent or legal guardian to provide written informed consent and, if applicable, pediatric assent and compliance with study assessments for the full duration of the study * Diagnosis of CF by sweat or genetic testing * Between the ages of 5 and 12 years for girls an...
Top 6 of 7 competitors
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| Vertex Pharmaceuticals Incorporated | VRTX | 8 | PHASE3 | Alyftrek, Trikafta, Ivacaftor, VX-581, VX-272 |
| BiomX Inc. | PHGE | 1 | PHASE2 | BX004 |
| 4D Molecular Therapeutics, Inc. | FDMT | 1 | PHASE2 | 4D-710 |
| Arcturus Therapeutics Holdings, Inc. | ARCT | 1 | PHASE2 | ARCT-032 |
| Krystal Biotech, Inc. | KRYS | 1 | PHASE1 | KB407 |
| Roivant Sciences Ltd. | ROIV | 1 | PHASE1 | SP-101 |
Nutropin AQ is a somatropin (DNA origin) injection developed by Roche Holding AG. It has been studied in cystic fibrosis, specifically for the treatment of growth restriction in children with the condition. The formulation is given as an injection and was evaluated in a Phase 2 clinical trial.
Nutropin AQ was studied for the treatment of growth restriction in children with cystic fibrosis. The Phase 2 trial enrolled children aged 5 years and older with cystic fibrosis. It was investigated as a treatment for growth restriction associated with the disease rather than as a therapy for the underlying lung condition itself.
Nutropin AQ is developed by Roche Holding AG, which trades under the ticker RHHBY. Roche is the company associated with the drug's clinical development in cystic fibrosis. The asset is a somatropin (DNA origin) injection.
Nutropin AQ is in Phase 2 development for cystic fibrosis. The single recorded trial, NCT00079742, is a completed Phase 2 study. The drug is investigational in this indication and is not described as approved for cystic fibrosis.
Nutropin AQ has been evaluated in one clinical trial, NCT00079742, titled A Study to Evaluate Nutropin AQ for the Treatment of Growth Restriction in Children With Cystic Fibrosis. It was a completed Phase 2 study that enrolled 68 participants aged 5 years and older. The trial was uncontrolled.
Yes, Nutropin AQ is also known as Nutropin AQ [somatropin (DNA origin) injection]. The bracketed form is the full descriptive name of the same product, identifying it as a somatropin (DNA origin) injection. Both names refer to the Roche Holding AG asset studied in cystic fibrosis.